News | May 06, 2024
Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated
